XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1Close
Consolidated Statements of Earnings - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues:        
Net earned premiums, principally supplemental health insurance [1] $ 3,325 $ 3,573 $ 6,781 $ 7,262
Net investment income 1,095 999 2,095 1,942
Net investment gains (losses) 696 555 1,647 678
Other income (loss) 22 45 52 90
Total revenues 5,138 5,172 10,575 9,972 Close
Benefits and expenses:        
Benefits and claims, excluding reserve remeasurement 1,972 2,152 4,039 4,354
Reserve remeasurement (gains) losses (51) (54) (107) (107)
Total benefits and claims, net 1,921 2,098 3,932 4,247
Acquisition and operating expenses:        
Amortization of deferred policy acquisition costs 208 202 424 407
Insurance commissions 246 268 501 547
Insurance and other expenses 694 728 1,431 1,505
Interest expense 50 51 97 99
Total acquisition and operating expenses 1,198 1,249 2,453 2,558
Total benefits and expenses 3,119 3,347 6,385 6,805 Close
Earnings before income taxes 2,019 1,825 4,190 3,167 Close
Income taxes 264 191 556 345 Close
Net earnings $ 1,755 $ 1,634 $ 3,634 $ 2,822 Close
Net earnings per share:        
Basic (in dollars per share) $ 3.11 $ 2.72 $ 6.38 $ 4.66
Diluted (in dollars per share) $ 3.10 $ 2.71 $ 6.35 $ 4.64
Weighted-average outstanding common shares used in computing earnings per share (In thousands):        
Basic (in shares) 564,573 600,742 569,730 605,945
Diluted (in shares) 566,838 602,929 572,160 608,411
Cash dividends per share $ 0.50 $ 0.42 $ 1.00 $ 0.84
[1] Includes a gain (loss) of $(2) and $(1) for the three-month periods and $(5) and $(1) for the six-month periods ended June 30, 2024 and 2023, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.